{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:59:33Z","timestamp":1792828773897,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Provincial Health Science and Technology Program","award":["2023KY570"],"award-info":[{"award-number":["2023KY570"]}]},{"name":"Social development Project of Public Welfare Technology Research in Zhejiang Province","award":["LGF21H160008"],"award-info":[{"award-number":["LGF21H160008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-04138-w","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T14:55:15Z","timestamp":1764773715000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predictive value of 18F-FDG-PET\/CT for pathologic complete response (pCR) of lesions after neoadjuvant chemotherapy in advanced ovarian cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Shiyu","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuyan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"4138_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/IJWH.S197604","volume":"11","author":"Z Momenimovahed","year":"2019","unstructured":"Momenimovahed Z, et al. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287\u201399.","journal-title":"Int J Womens Health"},{"issue":"6","key":"4138_CR2","first-page":"609","volume":"80","author":"MA Roett","year":"2009","unstructured":"Roett MA, Evans P. Ovarian cancer: an overview. Am Fam Physician. 2009;80(6):609\u201316.","journal-title":"Am Fam Physician"},{"issue":"13","key":"4138_CR3","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1042\/CS20190082","volume":"133","author":"M Alharbi","year":"2019","unstructured":"Alharbi M, et al. Ovarian cancer-derived exosomes promote tumour metastasis in vivo: an effect modulated by the invasiveness capacity of their originating cells. Clin Sci. 2019;133(13):1401\u201319.","journal-title":"Clin Sci"},{"issue":"1","key":"4138_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.hoc.2011.10.004","volume":"26","author":"JO Schorge","year":"2012","unstructured":"Schorge JO, Eisenhauer EE, Chi DS. Current surgical management of ovarian cancer. Hematol Oncol Clin North Am. 2012;26(1):93\u2013109.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"10","key":"4138_CR5","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943\u201353.","journal-title":"N Engl J Med"},{"key":"4138_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ygyno.2024.04.009","volume":"187","author":"S Piedimonte","year":"2024","unstructured":"Piedimonte S, et al. Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma. Gynecol Oncol. 2024;187:92\u20137.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4138_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ygyno.2015.10.018","volume":"140","author":"T Vallius","year":"2016","unstructured":"Vallius T, et al. 18F-FDG-PET\/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer. Gynecol Oncol. 2016;140(1):29\u201335.","journal-title":"Gynecol Oncol"},{"issue":"10","key":"4138_CR8","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1007\/s00259-021-05450-9","volume":"48","author":"RC Delgado Bolton","year":"2021","unstructured":"Delgado Bolton RC, et al. EANM guideline on the role of 2-[18F]FDG PET\/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer. Eur J Nucl Med Mol Imaging. 2021;48(10):3286\u2013302.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"4138_CR9","doi-asserted-by":"publisher","first-page":"W464","DOI":"10.2214\/AJR.09.3843","volume":"194","author":"P Prakash","year":"2010","unstructured":"Prakash P, Cronin CG, Blake MA. Role of PET\/CT in ovarian cancer. AJR Am J Roentgenol. 2010;194(6):W464\u201370.","journal-title":"AJR Am J Roentgenol"},{"issue":"22","key":"4138_CR10","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","volume":"33","author":"S B\u00f6hm","year":"2015","unstructured":"B\u00f6hm S, et al. Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol. 2015;33(22):2457\u201363.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4138_CR11","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.3802\/jgo.2017.28.e73","volume":"28","author":"JY Lee","year":"2017","unstructured":"Lee JY, et al. External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Gynecol Oncol. 2017;28(6):e73.","journal-title":"J Gynecol Oncol"},{"issue":"6","key":"4138_CR12","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1111\/cas.13605","volume":"109","author":"J Li","year":"2018","unstructured":"Li J, et al. Hypocrellin B-loaded, folate-conjugated polymeric micelle for intraperitoneal targeting of ovarian cancer in vitro and in vivo. Cancer Sci. 2018;109(6):1958\u201369.","journal-title":"Cancer Sci"},{"key":"4138_CR13","doi-asserted-by":"publisher","first-page":"106471","DOI":"10.1016\/j.intimp.2020.106471","volume":"84","author":"Y Yousefzadeh","year":"2020","unstructured":"Yousefzadeh Y, et al. Tumor-associated macrophages in the molecular pathogenesis of ovarian cancer. Int Immunopharmacol. 2020;84:106471.","journal-title":"Int Immunopharmacol"},{"key":"4138_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ygyno.2024.03.006","volume":"186","author":"S Ehmann","year":"2024","unstructured":"Ehmann S, et al. Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer. Gynecol Oncol. 2024;186:104\u20139.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"4138_CR15","first-page":"665","volume":"52","author":"YS Chung","year":"2020","unstructured":"Chung YS, et al. Early assessment of response to neoadjuvant chemotherapy with 18F-FDG-PET\/CT in patients with advanced-stage ovarian cancer. Cancer Res Treat. 2020;52(3):665\u201372.","journal-title":"Cancer Res Treat"},{"issue":"1","key":"4138_CR16","first-page":"81","volume":"55","author":"AA Martoni","year":"2011","unstructured":"Martoni AA, et al. [18F]FDG-PET\/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy. Q J Nucl Med Mol Imaging. 2011;55(1):81\u201390.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"9","key":"4138_CR17","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMoa1808424","volume":"380","author":"P Harter","year":"2019","unstructured":"Harter P, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med. 2019;380(9):822\u201332.","journal-title":"N Engl J Med"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04138-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04138-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04138-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:02:46Z","timestamp":1767837766000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-025-04138-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4138"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04138-w","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Medical Ethics Committee of Zhejiang Cancer Hospital (IRB-2024\u2013901). Informed consent for the use of clinical samples for medical study and the publication of results was provided by the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors give their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}